If necessary, the activity of heparin sodium can be monitored by measuring anti-xa.
Treatment of acute deep venous thrombosis
Dextroheparin sodium can be injected subcutaneously once a day or twice a day.
Usage: 200 IU/kg body weight, subcutaneous injection once a day. There is no need to monitor anticoagulant effects. Do not exceed 18,000 IU per day.
Use twice a day: 100 IU/kg body weight, subcutaneous injection twice a day, this dose is suitable for patients at higher risk of bleeding. Normally, no monitoring is required during treatment, but functional anti-xa can be measured. Blood samples were taken 3-4 hours after subcutaneous injection, and the maximum blood drug concentration could be measured. The recommended blood concentrations range from 0.5 to 1.0 IU of -xa /mL.
Continuous intravenous infusion usage: the recommended initial dose is 100IU/kg body weight and can be repeated every 12 hours.
This product can be taken immediately with the oral antagonist vitamin K. Treatment should be continued until prothrombin complex levels (factor ii.vii, IX, X) are reduced to therapeutic levels. The combination usually takes at least five days.
Prevent clotting during hemodialysis and blood filtration
Chronic renal failure with no known risk of bleeding:
Hemodialysis and blood filtration should not exceed 4 hours: dose as follows or intravenous rapid injection 5000 IU.
Hemodialysis and blood filtration over 4 hours: rapid intravenous infusion of 30-40 IU/kg body weight followed by intravenous infusion of 10-15 IU/kg body weight per hour.
Under normal circumstances, when patients receive long-term hemodialysis application of this product, the number of times they need to adjust the dose is very small, so the number of times they need to detect the concentration of anti-xa is also very small. The dose is usually administered to maintain the plasma concentration within the range of 0.5-1.0 IU of -xa /mL.
Acute renal failure with a high risk of bleeding:
Iv rapid infusion of 5-10 IU/kg body weight followed by iv infusion of 4-5 IU/kg body weight per hour.
Patients undergoing acute hemodialysis have a shorter treatment interval and should be fully monitored against -xa.
The plasma concentration of anti-xa should be maintained in the range of 0.2-0.4 IU anti-xa /mL.